SG11201806433VA - Composition and combined medication method for treating enterovirus infection - Google Patents

Composition and combined medication method for treating enterovirus infection

Info

Publication number
SG11201806433VA
SG11201806433VA SG11201806433VA SG11201806433VA SG11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA SG 11201806433V A SG11201806433V A SG 11201806433VA
Authority
SG
Singapore
Prior art keywords
composition
enterovirus infection
combined medication
medication method
treating
Prior art date
Application number
SG11201806433VA
Inventor
Gang Zou
Ralf Altmeyer
Yizhuo Wang
Original Assignee
Institut Pasteur Of Shanghai Chinese Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610067175.3A external-priority patent/CN105664166B/en
Priority claimed from CN201610067164.5A external-priority patent/CN105688216B/en
Application filed by Institut Pasteur Of Shanghai Chinese Academy Of Sciences filed Critical Institut Pasteur Of Shanghai Chinese Academy Of Sciences
Publication of SG11201806433VA publication Critical patent/SG11201806433VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSITION AND COMBINED MEDICATION METHOD FOR TREATING ENTEROVIRUS INFECTION The present invention provides a composition and a combined medication method for treating an enterovirus infection. In particular, the present invention provides a composition for inhibiting enteroviruses, wherein the composition at least comprises an inhibitor of a 3D virus protein and an inhibitor of a capsid protein, or a combination of an inhibitor of a 3C protein and an inhibitor of a 3A protein. (No Suitable Figure)
SG11201806433VA 2016-01-29 2017-01-11 Composition and combined medication method for treating enterovirus infection SG11201806433VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610067175.3A CN105664166B (en) 2016-01-29 2016-01-29 A kind of composition that treating enterovirus infection and drug combination method
CN201610067164.5A CN105688216B (en) 2016-01-29 2016-01-29 The component and drug combination method for treating enterovirus infection
PCT/CN2017/070858 WO2017128950A1 (en) 2016-01-29 2017-01-11 Composition and combined medication method for treating enterovirus infection

Publications (1)

Publication Number Publication Date
SG11201806433VA true SG11201806433VA (en) 2018-08-30

Family

ID=59397381

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806433VA SG11201806433VA (en) 2016-01-29 2017-01-11 Composition and combined medication method for treating enterovirus infection

Country Status (6)

Country Link
US (1) US10864210B2 (en)
JP (1) JP6644917B2 (en)
AU (1) AU2017210921B2 (en)
MY (1) MY201019A (en)
SG (1) SG11201806433VA (en)
WO (1) WO2017128950A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145608B (en) 2011-12-07 2015-09-02 南开大学 Anti-enteric virus71 (EV71) hexanolactam compounds and its production and use
CN105664166B (en) 2016-01-29 2019-05-10 中国科学院上海巴斯德研究所 A kind of composition that treating enterovirus infection and drug combination method
CN105688216B (en) 2016-01-29 2019-01-25 中国科学院上海巴斯德研究所 The component and drug combination method for treating enterovirus infection

Also Published As

Publication number Publication date
MY201019A (en) 2024-01-30
WO2017128950A1 (en) 2017-08-03
JP2019509331A (en) 2019-04-04
US20190030027A1 (en) 2019-01-31
JP6644917B2 (en) 2020-02-12
US10864210B2 (en) 2020-12-15
AU2017210921B2 (en) 2020-01-02
AU2017210921A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
MX2017008720A (en) Derivatives and methods of treating hepatitis b infections.
JOP20180008A1 (en) Compounds for the treatment of hepatitis b virus infection
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
MX2018005569A (en) Vaccines against hepatitis b virus.
MX2018005315A (en) Compositions and methods for treatment of cancer.
MX2019007256A (en) Phosphodiesterase inhibitors and methods of microbial treatment.
EA030115B9 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201792069A1 (en) DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B
MX2018008346A (en) Oncolytic virus and checkpoint inhibitor combination therapy.
MX2020004060A (en) Methods for treating hepatitis b infection.
MX2016016722A (en) Coronavirus.
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2018016057A (en) Compositions and methods for treating cardiovascular disease.
MX2021007602A (en) Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections.
MX2021004464A (en) Thiazolide compounds for treating viral infections.
MX2019005401A (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2017000312A (en) Isoindoline derivatives for use in the treatment of a viral infection.
MX2018009325A (en) Compounds and methods of treating rna-mediated diseases.
BR112017026061A2 (en) compound, use of a compound, and method of treating a viral infection
EP3681508A4 (en) Method and composition for treating viral infection
MX2017016114A (en) Methods of treating or preventing a proteopathy.
EP3658679C0 (en) Method for rapid detection and enumeration of viruses, bacteriophage and/or bacteria